| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5705149 | Ophthalmology | 2017 | 9 Pages |
Abstract
During the matched q8 phase, the BCVA in brolucizumab-treated eyes appeared comparable to aflibercept-treated eyes, with more stable CSFT reductions, receipt of fewer unscheduled treatments, and higher rates of fluid resolution. The brolucizumab safety profile was similar to aflibercept over 56 weeks of treatment. A 12-week treatment cycle for brolucizumab may be viable in a relevant proportion of eyes.
Keywords
BCVAintraretinal fluidevery 8 weeksIVTevery 4 weeksIRFSD OCTnAMDCSFTETDRSSAEiOpSRFQ12AMDFASfluorescein angiographybest-corrected visual acuityanalysis of varianceANOVASpectral-domain optical coherence tomographyintravitrealearly treatment diabetic retinopathy studyneovascular age-related macular degenerationLSMage-related macular degenerationcentral subfield thicknessadverse eventSerious adverse eventcolor fundus photographyconfidence intervalVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Intraocular pressureSubretinal fluidLeast squares mean
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Pravin U. MD, Glenn J. MD, Peter MBA, MD, James MBBS, Andreas PhD, Mark MD, Lawrence MD,